development and commercialization agreement for Iclusig
Reuters Insider - U.S. Morning Call: Cyber Monday sales hurt by discounts
Brief: Lundbeck's Abilify Maintena schizophrenia drug best in head-to-head study
"Smart pill" firm Proteus raises $172 million
Sanofi held talks with Abbott, Mylan about mature drugs -document (updated)
Corrected: Target tuberculosis in rich world as model for poor - WHO
Brief: Lundbeck, Otsuka launches schizophrenia drug in Europe
Brief: Lundbeck, Otsuka launches schizophrenia drug in Europe
Proteus picks UK for "smart pill" production and testing
Refile: UPDATE 3-Bayer bids $2.4 bln for Norwegian cancer drug partner Algeta
Bayer bids $2.4 bln for Norwegian cancer drug partner Algeta (updated)
Gilead and GSK drugs for HCV and HIV win EU green light (updated)
EU regulators back two new drugs for resistant tuberculosis
EU agency backs new drugs from GSK, Gilead, Otsuka
EU agency backs new drugs from GSK, Gilead, Otsuka
Brief: Otsuka, Lundbeck�s Abilify Maintena approved in EU
Brief: Lundbeck expands its partnership with Otsuka to Japan
Brief: Lundbeck, Otsuka get positive opinion for schizophrenia drug
Europe backs new dual-action Novartis lung drug (updated)